[1] Yu T, Li S, Zhang Z. Primary mixed large cell neuroendocrine carcinoma and adenocarcinoma of the gallbladder: a case report and literature review[J]. Asian J Surg, 2022, 45(11):2336-2338. [2] Fang S, Wang X, Wu X, et al. Therapeutic response analysis for patients with adenosquamous carcinoma of the gallbladder: data analysis based on the Surveillance, Epidemiology, and End Results (SEER) database[J]. J Gastrointest Oncol, 2023, 14(1):405-419. [3] Dhruv S, Atodaria K P, Mukherjee I, et al. Large cell neuroendocrine carcinoma of the gallbladder: where survival is a rare entity-case report and review of the literature[J]. Case Rep Gastroenterol, 2023, 17(1):333-338. [4] Akbar N, Yaseen T, Muhammad A, et al. A tertiary care center's experience with clinicopathological characteristics of gallbladder carcinoma in our population[J]. Euroasian J Hepatogastroenterol, 2022, 12(1):35-39. [5] 杜森, 鲍志国, 周青. 基于CT影像学指标和临床病理特征构建预测胆囊癌病人预后的列线图模型[J]. 安徽医药, 2023, 27(12):2397-2401. [6] Liu Z, Lyu X, Chen J, et al. Arnicolide C suppresses tumor progression by targeting 14-3-3θ in breast cancer[J]. Pharmaceuticals (Basel), 2024, 17(2):224-237. [7] Lee W T, Wu P Y, Cheng Y M, et al. Tissue inhibitor of metalloproteinase 3: unravelling its biological function and significance in oncology[J]. Int J Mol Sci, 2024, 25(6):3191-3211. [8] 中华医学会外科学分会胆道外科学组, 中国医师协会外科医师分会胆道外科专业委员会. 胆囊癌诊断和治疗指南(2019版)[J]. 中华外科杂志, 2020, 58(4):243-251. [9] 王鹏, 邱振东, 张利龙, 等. 白细胞分化抗原74在胆囊癌中的表达及其与表皮生长因子受体表达的相关性分析[J]. 临床外科杂志, 2022, 30(10):977-980. [10] Minagawa T, Itano O, Hasegawa S, et al. Short-and long-term outcomes of laparoscopic radical gallbladder resection for gallbladder carcinoma: a multi-institutional retrospective study in Japan[J]. J Hepatobiliary Pancreat Sci, 2023, 30(8):1046-1054. [11] 李庆贺, 樊斌, 张家耀, 等. RELMβ和CDX-2在胆囊癌中的表达及临床意义[J]. 中国现代普通外科进展, 2022, 25(10):832-835. [12] Hong L, Chen M, Huang M, et al. FOXA2 suppresses gallbladder carcinoma cell migration, invasion, and epithelial-mesenchymal transition by targeting SERPINB5[J]. Environ Toxicol, 2024, 39(2):708-722. [13] Varl? M, Bhosle S R, Kim E, et al. Usnic acid targets 14-3-3 proteins and suppresses cancer progression by blocking substrate interaction[J]. JACS Au, 2024, 4(4):1521-1537. [14] Jung J Y, Koh S A, Lee K H, et al. 14-3-3 sigma protein contributes to hepatocyte growth factor-mediated cell proliferation and invasion via matrix metalloproteinase-1 regulation in human gastric cancer[J]. Anticancer Res, 2022, 42(1):519-530. [15] Chen Z, Zheng L, Chen Y, et al. Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3ζ protein and represses lung cancer metastasis[J]. Cancer Biol Ther, 2022, 23(1):265-280. [16] Lu X, An L, Fan G, et al. EGFR signaling promotes nuclear translocation of plasma membrane protein TSPAN8 to enhance tumor progression via STAT3-mediated transcription[J]. Cell Res, 2022, 32(4):359-374. [17] Li W, Song Y Y, Rao T, et al. CircCSNK1G3 up-regulates miR-181b to promote growth and metastasis via TIMP3-mediated epithelial to mesenchymal transitions in renal cell carcinoma[J]. J Cell Mol Med, 2022, 26(6):1729-1741. [18] Chung J F, Chen C L, Nassef Y, et al. Effect of tissue inhibitor of metalloproteinases-3 genetics polymorphism on clinicopathological characteristics of uterine cervical cancer patients in Taiwan[J]. Int J Med Sci, 2022, 19(6):1013-1022. [19] 李和丽, 梁殿迅, 王秋宇, 等. miR-21靶向调节TIMP3/MMP9信号通路对宫颈癌细胞增殖、凋亡和迁移的影响[J]. 中国老年学杂志, 2023, 43(23):5800-5804. [20] 刘学停, 蔡军, 孙艳军, 等. miR-181靶向TIMP3调控胆囊癌细胞迁移及侵袭的实验研究[J]. 安徽医科大学学报, 2021, 56(4):514-519. [21] Li W, Song Y Y, Rao T, et al. CircCSNK1G3 up-regulates miR-181b to promote growth and metastasis via TIMP3-mediated epithelial to mesenchymal transitions in renal cell carcinoma[J]. J Cell Mol Med, 2022, 26(6):1729-1741. [22] 杨阳, 贾万理, 晋婕. miR-187、MMP2、CEA在胆囊癌患者中的表达水平及临床意义[J].检验医学与临床, 2022, 19(16):2239-2241+2245. |